Skip to Content

Tapan M. Kadia, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2001 Robert Wood Johnson Medical School, Piscataway, NJ, MD, Doctor of Medicine
1998 Rutgers University, New Brunswick, NJ, BA, Bachelor of Arts

Postgraduate Training

7/2004-6/2005 Chief Residency, Baylor College of Medicine Affiliated Hospitals, Houston, TX
7/2002-6/2004 Clinical Residency, Baylor College of Medicine Affiliated Hospitals, Houston, TX
7/2001-6/2002 Clinical Internship, Baylor College of Medicine Affiliated Hospitals, Houston, TX

Board Certifications

8/2004 Internal Medicine, American Board of Internal Medicine

Honors and Awards

2006 AACR/ASCO Workshop Methods in Clinical Cancer Research Vail
2006 AACR/ASCO Workshop Molecular Biology in Clinical Oncology Aspen
2006 FOREM Lymphoma Research Award, Runner up
2006 Recipient of The Paul Calabresi Clinical Oncology Award-K12 Grant
2004 Chief Residency, Internal Medicine, Baylor College of Medicine
2000 Articulated BA/MD Program
2000 Dean's List, Rutgers College
2000 Member, Golden Key National Honor Society
2000 Member, Phi Beta Kappa Honor Society
2000 Member, Phi Eta Sigma Honor Society
2000 Recipient of The Waksman Fellowship for Undergraduate Research
2000 UMDNJ Research Fellowship
1998 Norman Reitman Scholoar
1996 Rutgers College Award of Excellence
1995 Rutgers College Award of Excellence

Professional Memberships

American Association of Cancer Research (AACR)
Associate Member, 1/2000
American Society of Clinical Oncology (ASCO)
Associate Member, 1/2000
American Society of Hematology (ASH)
Associate Member, 1/2000

Selected Publications

Peer-Reviewed Original Research Articles
1. Mendez J, Kadia TM , Somayazula RK, El-Badawi KI, Cowen DS. Differential coupling of serotonin 5-HT1A and 5-HT1B receptors to activation of ERK2 and inhibition of adenylyl cyclase in transfected CHO cells. J Neurochem 73(1):162-8, 7/1999. PMID: 10386967.

Abstracts
1. Kadia TM , Ferrajoli A, Ravandi F, Cortes J, Thomas D, Wierda W, Verstosvek S, Newsom W, Zwiebel J, Egorin M, Kantarjian H, Garcia-Manero G. A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia. Poster Presentation, American Society of Hematology Meeting, 12/2007.
2. Thompson MA, Kadia TM , Bekele BN, Wang M, Romaguera JE. Cyclin D1 polymorphisms as predictive and prognostic molecular markers in 90 mantle cell lymphoma patients treated with R-HyperCVAD. Poster Presentation, American Society of Hematology, 12/2007.
3. Kadia TM , Kantarjian H, Verstovesek S, Newman B, Garcia-Manero G, Borthakur G. Treatment of Myelodysplastic Syndrome (MDS) with Cytokine Immunotherapy for Low-Risk MDS. Poster Presentation, American Society of Hematology Meeting, 12/2007.
4. Kadia TM , Borthakur G, Wierda W, Ravandi F, Faderl S, Newsome W, Zwiebel J, Egorin M, Garcia-Manero G. Phase I Study of the Combination of a DNA Topoisomerase Inhibitor, Idaruicin, with the Histone Daecetylase Inhibitor Vorinostat in Advanced Leukemia. Poster Presentation, American Society of Clinical Oncology Meeting, 5/2007.
5. Kadia TM, Rodriguez A, Fayad L, Mclaughlin P, Pro B. Retrospective Review of Angioimmunoblastic T-Cell Lymphoma: The MD Anderson Cancer Center Experience. American Society of Hematology Meeting, 12/2006.
6. Kadia TM , Kleinbaum E. Atypical Cutaneous Presentation of Acute Monocytic Leukemia. Poster Presentation, Baylor College of Medicine Annual Research Symposium, 6/2005.

Last updated: 10/12/2010